NEW YORK, October 3, 2017 /PRNewswire/ --
If you want a Stock Review on IPXL, GSK, NVS, or TXMD then come over tohttp://dailystocktracker.com/register/ and sign up for your free customized report today. On Monday, October 02, 2017, US markets saw broad based gains with eight out of nine sectors finishing the trading sessions in
On Monday, shares in Hayward, California headquartered Impax Laboratories Inc. recorded a trading volume of 2.18 million shares. The stock ended the session 5.91% higher at $21.50. The Company's shares have gained 31.10% over the previous three months and 62.26% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 9.48% and 41.30%, respectively. Moreover, shares of Impax Labs, which develops, manufactures, and markets bioequivalent pharmaceutical products, have a Relative Strength Index (RSI) of 53.00. Visit us today and download your complete report on IPXL for free at: http://dailystocktracker.com/registration/?symbol=IPXL
Brentford, the UK headquartered GlaxoSmithKline PLC's stock closed the day 0.76% higher at $40.91 with a total trading volume of 2.24 million shares. The Company's shares have advanced 6.23% since the start of this year. The stock is trading above its 50-day moving average by 2.02%. Additionally, shares of GlaxoSmithKline, which engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide, have an RSI of 61.72.
On September 08th, 2017, research firm Morgan Stanley downgraded the Company's stock rating from 'Equal-Weight' to 'Underweight'. The complimentary research report on GSK can be accessed at: http://dailystocktracker.com/registration/?symbol=GSK
Shares in Basel, Switzerland headquartered Novartis AG recorded a trading volume of 2.00 million shares, which was above their three months average volume of 1.60 million shares. The stock ended yesterday's trading session 0.57% higher at $86.34. The Company's shares have advanced 18.53% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 2.12% and 9.53%, respectively. Furthermore, shares of Novartis, which researches, develops, manufactures, and markets healthcare products worldwide, have an RSI of 58.36. Register for free on DailyStockTracker.com and download the research report on NVS at: http://dailystocktracker.com/registration/?symbol=NVS TherapeuticsMD
Boca Raton, Florida headquartered TherapeuticsMD Inc.'s stock finished Monday's session 2.46% lower at $5.16 with a total trading volume of 4.90 million shares, which was above their three months average volume of 2.59 million shares. The stock is trading below its 50-day moving average by 13.02%. Additionally, shares of TherapeuticsMD, which operates as a women's health care product company, have an RSI of 34.46.
On September 08th, 2017, research firm Morgan Stanley initiated an 'Equal-Weight' rating on the Company's stock, with a target price of $6 per share. Get free access to your research report on TXMD at: http://dailystocktracker.com/registration/?symbol=TXMD
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://dailystocktracker.com/disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Subscribe to our Free Newsletters!
Sea food allergy is the adverse response of the body''s immune system to the proteins present in ...
Yellow fever is a hemorrhagic fever that is transmitted by infected mosquitoes and it can lead to ...
Routes of drug administration play a major role in a medical treatment. Selecting a right route of ...View All